扶正抑瘤法对前列腺癌患者原发灶树突状细胞数量及活化的影响
|
摘要
背景
前列腺癌是男性常见的恶性肿瘤之一。在美国其发病率居男性恶性肿瘤之首,在我国其发病率已跃居泌尿系肿瘤的第3位。前列腺癌患者确诊时多数已属晚期,并且几乎所有患者经内分泌治疗一段时期后都转变为雄激素非依赖型前列腺癌,因此成为现代医学的治疗难点。广东省中医院泌尿外科多年来潜心研究前列腺癌,通过中医证候调查,发现D_0期前列腺癌中医辨证多属脾虚证、肾气虚证。D_1期前列腺癌中医辨证多属血瘀证,下焦湿热证。D_2期前列腺癌中医辨证多属脾虚证、血瘀证、下焦湿热证、肾气虚证、阴虚痰热证和肾阴虚热证。D_3前列腺癌中医辨证多属气血两虚证,肾阳虚证。根据证候调查结果,结合现代医学进展,制定了以扶正抑瘤为主法的中西医结合方案,治疗本院住院及门诊前列腺癌病例142例,统计分析总生存率、总体中位生存期、总体无进展生存率、骨转移灶数目、PSA、血细胞分析、QLQ-C30量表、并发症发生率等,观察扶正抑瘤法对前列腺癌的实际临床疗效,随访时间1～50月,观察期间死亡16例,总生存率90.14%,总体中位生存期27.7月,总体无进展中位时间25.2个月。PSA复发时间23.9±19.2个月,PSA倍增时间24.1±20.4个月。QLQ-C30量表标准分统计,症状改善有效率81.0%。潮热症状发生率22.4%,骨质疏松发生率13.8%;乳房肿痛发生率11.7%。其中T3～4NxMlb期110例患者总体无进展生存期24.3个月。去势后PSA最低值0,PSA复发时间20.1±15.2个月,PSA倍增时间22.3±17.4个月。骨转移灶消失4例,缩小、变淡79例,无扩散、无增多18例,出现新的转移灶9例,在提高生存质量、延缓肿瘤转移及进展等方面,显示了中医药良好的前景。同时在临床实践中发现前列腺癌患者的细胞免疫功能均低下,大部分患者的细胞免疫功能在应用扶正抑瘤中西医结合治疗后有一定变化,并呈现提高的趋势,这些结果正是越来越受重视的肿瘤免疫治疗所希望达到的目的,而抗肿瘤免疫中特异性细胞免疫中占主导地位。树突状细胞是人体功能最强大的抗原提呈细胞,是特异性免疫的启动者。既然扶正抑瘤法已经初步体现其在细胞免疫调节中的前景,因此,有必要对其在前列腺癌患者体内树突状细胞的影响进一步探索。
目的
在既往前列腺癌的病因病机、证候规律研究、中西医结合治疗方案对生存质量及PSA、骨转移灶临床疗效研究以及中西医治疗对前列腺癌患者细胞免疫的研究的基础上,应用分别反映树突状细胞的总体数量和活化能力的分子CD1a和CD83在前列腺癌原发灶病理切片中标记树突状细胞,探讨扶正抑瘤法对前列腺癌患者原发灶树突状细胞的数量及活化的影响。
方法
本研究采用前瞻性平行对照实验设计,病例来源:2005年1月至2009年1月广东省中医院确诊前列腺癌的住院病人57例,根据病理资料和不同的处理方法分为两组,每组分两个亚组。其中第一组18例患者均取得2次病理标本,其中亚组中西医结合治疗组10例,亚组内分泌治疗组8例,中西医结合治疗组采用“扶正抑瘤”中西结合治疗方案(扶正抑瘤中药+常规内分泌治疗),内分泌治疗组采用常规内分泌治疗方案,治疗时间根据两次取病理时间间隔7天到105天不等;第二组39例患者仅获得1次病理标本,按照病理活检前作为疑似前列腺癌病例时有否接受扶正抑瘤中药早期干预治疗分为亚组中药治疗组和亚组空白对照组,两组未病理确诊前均未接受内分泌治疗;其中中药治疗组19例,在获得病理诊断前作为疑似病例已经使用扶正抑瘤中药,治疗时间7到25天不等,平均8.7天;空白对照组20例,病理诊断前未使用任何治疗措施。用免疫组化技术Envision两步法染色标记所有前列腺癌患者(包括两个组所有亚组的患者)原发灶病理切片的CD1a阳性细胞及CD83阳性细胞。光镜下观察记录这些被标记的树突状细胞数量,阴性病理切片计数为0。进行统计学分析比较中西医结合治疗组与内分泌治疗组、中药组与空白组、中西医结合组与中药组、中药组与内分泌治疗组的CD1a和CD83阳性树突状细胞的均数。成组均数若符合正态分布时比较用成组t检验,不符合正态分布时比较用非参数检验(Mann-Whitney Test)检验,p≤0.05为差异有显著性。配对均数符合正态分布时用配对t检验,不符合正态分布时比较用非参数检验(Wilcoxon秩和检验),p≤0.05为差异有显著性,统计运用SPSS13.0软件包。
结果
1、第一组18例患者,其中中西医结合治疗组10例,内分泌治疗对照组8例,中西医结合组治疗前1例CD1a阴性、1例CD83阴性。内分泌治疗对照组治疗后1例CD1a阴性、1例CD83阴性。中西医结合治疗组治疗后的CD1a阳性树突状细胞数量均比治疗前升高,差异有统计学意义,P＜0.05;内分泌治疗组治疗后的CD1a阳性树突状细胞数量均比治疗前升高,差异有统计学意义,P=0.05。中西医结合治疗组治疗后的CD83阳性树突状细胞数量比治疗前升高,差异有统计学意义P＜0.05,内分泌治疗组治疗后的CD83阳性树突状细胞数量比治疗前略高,差异无统计学意义,P＞0.05;中西医结合治疗组CD1a阳性树突状细胞治疗前后差值高于内分泌治疗组,差异无统计学意义,P＞0.05。中西医结合治疗组CD83阳性树突状细胞治疗前后差值高于内分泌治疗组,差异有统计学意义,P＜0.05。
2、第二组患者39例,其中中药治疗组19例,空白对照组20例,中药治疗组1例CD1a阴性;空白对照组3例CD1a阴性、2例CD83阴性。中药治疗组CD1a阳性树突状细胞的数量比空白对照组高,差异有统计学意义,P＜0.05,中药治疗组CD83阳性树突状细胞的数量比空白对照组高,差异有统计学意义,P＜0.05。
3、中西医结合治疗组的CD83阳性的树突状细胞数量比中药治疗组高,差异有统计学意义,P＜0.05。中西医结合治疗组的CD1a阳性的树突状细胞数量比中药治疗组高,差异无统计学意义,P＞0.05。中药组CD1a阳性的树突状细胞数量比内分泌治疗组低,差异无统计学意义,P＞0.05;中药组CD83阳性的树突状细胞数量比内分泌治疗组高,差异无统计学意义,P＞0.05。
4、各种扶正抑瘤中药方案中,中药针剂+中药汤剂组比单纯中药汤剂组的CD1a、CD83均数高,差异有统计学意义,P＜0.05。
5、镜下观察可见空白对照组前列腺癌患者的原发灶CD1a、CD83阳性树突状细胞细胞呈胞浆及细胞核染色,形态欠成熟,伸出伪足不明显,染色较前列腺增生组织浅,数目减少以CD83阳性细胞明显。树突状细胞在癌周间质分布较多,在癌组织中分布较少,一般在癌周淋巴细胞浸润处分布较多。扶正抑瘤中药治疗组治疗后前列腺癌患者的原发灶树突状细胞的数量明显增多,在癌及癌周均有分布,染色较深,树突状细胞亦多分布在癌周较多淋巴细胞浸润处,淋巴细胞浸润较空白组密集,CD83阳性细胞形态较空白对照组成熟,伸出伪足明显,数个叠连,染色较深。
结论
1、前列腺癌患者原发灶树突状细胞的总体数量较良性前列腺组织减少、活化受抑制。扶正抑瘤中西医治疗方案的应用能在一定治疗时段提高前列腺癌患者原发灶的树突状细胞的总体数量及活化能力。
2、中西医结合、中药针剂与汤剂联用等治疗方案在一定治疗时段显示出在提高前列腺患者树突状细胞的总体数量与活化方面的联合效应优势。
3、使用扶正抑瘤中药后,前列腺癌原发灶树突状细胞的数量增多和活化能力提高的同时能观察到局部淋巴细胞数量增加,其可能机制是树突状细胞活化后有效提呈肿瘤抗原,激活淋巴细胞,引起淋巴细胞增值,从而启动特异性细胞免疫。
Background
Prostate cancer(PCa) is one of the malignant tumors of man's reprodu ctive system.In US,the incidence of prostate cancer is listed in the fi rst place of the man's malignant tumors'.In China,its incidence has be en up rising to the 3~(rd) place of all the urinary tumors'.Most of the indi viduals were diagnosed to be prostate cancer in their later period of can cer progression.Moreover,nearly all of the patients who had received th e incretion therapy would eventually turn to be the hormone refractory ca ses.This makes it tough for Modern Medicine to cure.Urinary Surgical De partment of Guangdong Provincial Hospital of Chinese Medicine had for lon g concentrated on the study of prostate cancer,and had initially explore d its etiology,pathogenesis and syndrome differentiation.The regular pa tterns of Prostate cancer are as follows:Phase D_0:spleen Qi deficiency, kidney Qi deficiency.Phase D_1:blood stasis,lower energizer damp-heat, kidney Qi deficiency.Phase D_2:spleen Qi deficiency,blood stasis,lowe r energizer damp-heat,kidney Qi deficiency,Yin deficiency and phlegm he at,deficiency heat.Phase D_3:Qi and blood deficiency.The according int egrative treatment protocols according to TCM concept "Fuzhengyiliufa" w hich has enhancive effect of quality of life and postponement of tumor pr ogress and metestasis had later been developed,demonstrated good prospec t in clinical used.Prospective study of 142 available cases of inpatient or outpatient in Guangdong hospital of TCM from Sep.2004 to Mar.2007 h ad been conducted.The treat period was 9 months.Collected information o f Karnofsky table、weight、QLQ-C30 table、I—PSS table、ache ctassificatio n table of WHO、table for research in symptom category of prostate cancer in D period、PSA、blood testosterone、ECT of systemic bones、analysis of blood corpuscle.The remedy group is obviously better than the control group in increasing weight,improving the scale of Karnofsky table,alle viating symptoms such as tiredness、pain、insomnia、appetite losing、p ressing breach、constipation、diarrhea,improving the emotion function a nd health condition in whole;improving the symptom of lower urethra;red ucing the incidence rate of the symptom such as tiredness and fatigue,in somnia,desudation,poor appetite,difficult in urethra,pain in waist an d knee,etc.,reducing the amount of PSA and bone metastasis(P＜0.05),enh ancing the amount of blood corpuscle such as WBC、HGB、PLT in circulation. In recent clinical practice,cellular immunity function decline was seen in all prostate cancer patients.While majority of patients' cellular im munity function were seen to be enhanced after the application of "Fuzhen gyiliufa" integrative treatment.This is precisely the same goal that all immunotherapies take hope to achieve.In human immune system,specific c ellular immunity plays a key role in fighting against tumor.While dendri tic cell(DC) is deemed to be the most powerful antigen precenting cells, which is the initiator of specific immunity.However,dendritic cell-bas ed immunotherapies only manifest the transient curative effect in partial PCa patients.Since "Fuzhengyiliufa" has been observed to have effect i n immunity function,its influence in dendritic cell should be further ex plored.
Purposes
To observe the infiltration and activation of dendritic cell in prima ry foci of prostate cancer using "Fuzhengyiliufa" integrative treatments.
Methods
Perspective research,control trail,57 prostate cancer in-patients w ere intaken in the study.The first group 18 patients,who had obtained p athological specimens before and after treatments respectively,were divi ded into two subgroups,therapeutic group 10 patients,and control group 8 patients.The therapeutic group received "Fuzhengyiliufa" integrative t reatment("Fuzhengyiliufa" TCM treatments combined with routine incretion therapy),the control group receieved routine incretion therapy,and the therapeutic period ranged between 7 days to 105 days.The second group 3 9 patients,who had only obtained 1 pathological specimen in each,were d ivided into two subgroups according to whether patients received "Fuzheng yiliufa" TCM treatment or not before their biopsy:therapeutic group 19 pa tients;blank control group 20 patients.The therapeutic group received "Fuzhengyiliufa" TCM treatments,the therapeutic period ranged between 7 to 25 days,8.7 days in average;control group didin't received any trea tment,then marked the CD1a positive dendritic cell and the CD83 positive dendritic cell which infiltrated in these pathological sections with the immunohistochemistry technique of "Envision" two step staining,and rec orded the quantities of these dendritc cells with microscope.The negativ e ones would be recorded as "0" in quatity.As for statistics analysis, dependent t-test would be used to compare means of dependent groups if th e variance meets Gaussion distribution,if not,non-parametric test(Mann -Whitney Test) would be applied,p＜0.05 has the significance for the diff erence.Pair groups t-test would be used to compare means of pair groups if the variance meets Gaussion distribution,if not,non-parametric test (Wilcoxon Test) would be applied,p＜0.05 has the significance for the dif ference.Statistic analysis software SPSS13.0 would be applied.
Results
1.The first group 18 patients who had obtained twice pathologic samp les in each,therapeutic subgroup 10 patients,with 1 before treatment sa mple CDla negative and 1 before treatment sample CD83 negative;Control s ubgroup 8 patients,with 1 after treatment sample CD1a negative and 1 aft er treatment sample CD83 negative.The quantity of CD1a positive DC after treatment in both groups elevated compared to the quantity of CD1a befor e treatments,the differences had statistical significance.The quantity of CD83 positive DC after treatment in therapeutic group elevated compare d to the quantity of CD83 positive DC before treatment,the differences h ad statistical significance,P≤0.05.The quantity of CD83 positive DC af ter treatment in control group elevated compared to the quantity of CD83 positive DC before treatment,the differences had no statistical signific ance,P＞0.05.The quantity difference of CD1a positive DC of therapeutic group were more than the ones of control group,the differences had no st atistical significance,P＞0.05.The quantity differences of CD83 positive DC of therapeutic group were more than the ones of control group,the di fferences had statistical significance,P＜0.05.
2.The second group 39 patients,who had obtained one pathologic samp le,therapeutic group 19 patients,with 1 sample CD1a negative;blank con trol group 20 patients,with 3 sample CD1a negative and 2 sample CD83 neg ative.The quantity of CD1a positive DC in therapeutic group surpass blan k control group,the difference had statistical significance,P＜0.05.The quantity of CD83 positive DC in therapeutic group surpass blank control group,the difference had statistical significance,P＜0.05.
3.Single use of "Fuzhengyiliufa" Chinese Medicine group elevated CD8 3 in quantity compared to blank control group,the differernce had statis tical significance,P＜0.05.
4.In descriptive study of comparision of various "Fuzhengyiliufa" tr eatments,it could be seen that the CD1a、CD83 elevating effect of conbine d used of herbal decortions and herbal injections were better than single use of herbal decortion,the differences had statistical significance,P＜0.05.
5.It could be observed with microscope in blank control group PCa pa tients' pathological section that the infiltrated dendritic cell declined in quatity and disfunction in activating.Marked by CD1a and CD83,dendr itic cells were stained in their cytoplasmid and nuclear,appeared immatu re in shape that less like dendritic form.Their staining is lighter than the ones in benign hyperplasia tissues,with prominent decline in CD83. Dendritic cell infiltration is more concentrating in mesenchrymal tissues beside tumor tissue with infiltrated lymphocyte arround.In therapeutic group PCa patients' pathological sections,infiltrated dendritic cell are much more in quantity.Dendritic cell infiltration is more concentrating, not only in mesenchrymal tissues but also in between the tumor cells.Th ey appeared more mature in dendritic form,staining darker.Moreover,the dendritic cells,marked by CD83,are more mature in shape with more conc entrating infiltrated lymphocytes around.
Conclusions
1.Infiltrated dendritic cells in prostate cancer primary foci were l ess than the ones in benign hyperplasia tissues in quantity.Their activa tion was inhibited.The application of "Fuzhengyiliufafa" integrative tr eatment protocol could increase the quantity of dendritic cell in prostat e cancer primary foci and greatly enhance their activating ability in cer tain therapeutic period.
2.It could be seen that the DC quantity elevating effect and the DC activation reinforcement effect of integrative therapy of Chinese Medicin e and incretion therapy and the combination of herbal decortions and inje ctions had advantage over other single used treatments.
3.It could be observed that with the elevated quantity and activatin g ability of dendritic cell,local lymphocytes infiltration became more c oncentrating.The probable mechanism was that activating dendritic cells precent tumor antigens to activate T lymphocytes.That leads to prolifera tion and expansion of T lymphocyte.In that way specific immunity was ini tiated.
前列腺癌是男性常见的恶性肿瘤之一。在美国其发病率居男性恶性肿瘤之首,在我国其发病率已跃居泌尿系肿瘤的第3位。前列腺癌患者确诊时多数已属晚期,并且几乎所有患者经内分泌治疗一段时期后都转变为雄激素非依赖型前列腺癌,因此成为现代医学的治疗难点。广东省中医院泌尿外科多年来潜心研究前列腺癌,通过中医证候调查,发现D_0期前列腺癌中医辨证多属脾虚证、肾气虚证。D_1期前列腺癌中医辨证多属血瘀证,下焦湿热证。D_2期前列腺癌中医辨证多属脾虚证、血瘀证、下焦湿热证、肾气虚证、阴虚痰热证和肾阴虚热证。D_3前列腺癌中医辨证多属气血两虚证,肾阳虚证。根据证候调查结果,结合现代医学进展,制定了以扶正抑瘤为主法的中西医结合方案,治疗本院住院及门诊前列腺癌病例142例,统计分析总生存率、总体中位生存期、总体无进展生存率、骨转移灶数目、PSA、血细胞分析、QLQ-C30量表、并发症发生率等,观察扶正抑瘤法对前列腺癌的实际临床疗效,随访时间1～50月,观察期间死亡16例,总生存率90.14%,总体中位生存期27.7月,总体无进展中位时间25.2个月。PSA复发时间23.9±19.2个月,PSA倍增时间24.1±20.4个月。QLQ-C30量表标准分统计,症状改善有效率81.0%。潮热症状发生率22.4%,骨质疏松发生率13.8%;乳房肿痛发生率11.7%。其中T3～4NxMlb期110例患者总体无进展生存期24.3个月。去势后PSA最低值0,PSA复发时间20.1±15.2个月,PSA倍增时间22.3±17.4个月。骨转移灶消失4例,缩小、变淡79例,无扩散、无增多18例,出现新的转移灶9例,在提高生存质量、延缓肿瘤转移及进展等方面,显示了中医药良好的前景。同时在临床实践中发现前列腺癌患者的细胞免疫功能均低下,大部分患者的细胞免疫功能在应用扶正抑瘤中西医结合治疗后有一定变化,并呈现提高的趋势,这些结果正是越来越受重视的肿瘤免疫治疗所希望达到的目的,而抗肿瘤免疫中特异性细胞免疫中占主导地位。树突状细胞是人体功能最强大的抗原提呈细胞,是特异性免疫的启动者。既然扶正抑瘤法已经初步体现其在细胞免疫调节中的前景,因此,有必要对其在前列腺癌患者体内树突状细胞的影响进一步探索。
目的
在既往前列腺癌的病因病机、证候规律研究、中西医结合治疗方案对生存质量及PSA、骨转移灶临床疗效研究以及中西医治疗对前列腺癌患者细胞免疫的研究的基础上,应用分别反映树突状细胞的总体数量和活化能力的分子CD1a和CD83在前列腺癌原发灶病理切片中标记树突状细胞,探讨扶正抑瘤法对前列腺癌患者原发灶树突状细胞的数量及活化的影响。
方法
本研究采用前瞻性平行对照实验设计,病例来源:2005年1月至2009年1月广东省中医院确诊前列腺癌的住院病人57例,根据病理资料和不同的处理方法分为两组,每组分两个亚组。其中第一组18例患者均取得2次病理标本,其中亚组中西医结合治疗组10例,亚组内分泌治疗组8例,中西医结合治疗组采用“扶正抑瘤”中西结合治疗方案(扶正抑瘤中药+常规内分泌治疗),内分泌治疗组采用常规内分泌治疗方案,治疗时间根据两次取病理时间间隔7天到105天不等;第二组39例患者仅获得1次病理标本,按照病理活检前作为疑似前列腺癌病例时有否接受扶正抑瘤中药早期干预治疗分为亚组中药治疗组和亚组空白对照组,两组未病理确诊前均未接受内分泌治疗;其中中药治疗组19例,在获得病理诊断前作为疑似病例已经使用扶正抑瘤中药,治疗时间7到25天不等,平均8.7天;空白对照组20例,病理诊断前未使用任何治疗措施。用免疫组化技术Envision两步法染色标记所有前列腺癌患者(包括两个组所有亚组的患者)原发灶病理切片的CD1a阳性细胞及CD83阳性细胞。光镜下观察记录这些被标记的树突状细胞数量,阴性病理切片计数为0。进行统计学分析比较中西医结合治疗组与内分泌治疗组、中药组与空白组、中西医结合组与中药组、中药组与内分泌治疗组的CD1a和CD83阳性树突状细胞的均数。成组均数若符合正态分布时比较用成组t检验,不符合正态分布时比较用非参数检验(Mann-Whitney Test)检验,p≤0.05为差异有显著性。配对均数符合正态分布时用配对t检验,不符合正态分布时比较用非参数检验(Wilcoxon秩和检验),p≤0.05为差异有显著性,统计运用SPSS13.0软件包。
结果
1、第一组18例患者,其中中西医结合治疗组10例,内分泌治疗对照组8例,中西医结合组治疗前1例CD1a阴性、1例CD83阴性。内分泌治疗对照组治疗后1例CD1a阴性、1例CD83阴性。中西医结合治疗组治疗后的CD1a阳性树突状细胞数量均比治疗前升高,差异有统计学意义,P＜0.05;内分泌治疗组治疗后的CD1a阳性树突状细胞数量均比治疗前升高,差异有统计学意义,P=0.05。中西医结合治疗组治疗后的CD83阳性树突状细胞数量比治疗前升高,差异有统计学意义P＜0.05,内分泌治疗组治疗后的CD83阳性树突状细胞数量比治疗前略高,差异无统计学意义,P＞0.05;中西医结合治疗组CD1a阳性树突状细胞治疗前后差值高于内分泌治疗组,差异无统计学意义,P＞0.05。中西医结合治疗组CD83阳性树突状细胞治疗前后差值高于内分泌治疗组,差异有统计学意义,P＜0.05。
2、第二组患者39例,其中中药治疗组19例,空白对照组20例,中药治疗组1例CD1a阴性;空白对照组3例CD1a阴性、2例CD83阴性。中药治疗组CD1a阳性树突状细胞的数量比空白对照组高,差异有统计学意义,P＜0.05,中药治疗组CD83阳性树突状细胞的数量比空白对照组高,差异有统计学意义,P＜0.05。
3、中西医结合治疗组的CD83阳性的树突状细胞数量比中药治疗组高,差异有统计学意义,P＜0.05。中西医结合治疗组的CD1a阳性的树突状细胞数量比中药治疗组高,差异无统计学意义,P＞0.05。中药组CD1a阳性的树突状细胞数量比内分泌治疗组低,差异无统计学意义,P＞0.05;中药组CD83阳性的树突状细胞数量比内分泌治疗组高,差异无统计学意义,P＞0.05。
4、各种扶正抑瘤中药方案中,中药针剂+中药汤剂组比单纯中药汤剂组的CD1a、CD83均数高,差异有统计学意义,P＜0.05。
5、镜下观察可见空白对照组前列腺癌患者的原发灶CD1a、CD83阳性树突状细胞细胞呈胞浆及细胞核染色,形态欠成熟,伸出伪足不明显,染色较前列腺增生组织浅,数目减少以CD83阳性细胞明显。树突状细胞在癌周间质分布较多,在癌组织中分布较少,一般在癌周淋巴细胞浸润处分布较多。扶正抑瘤中药治疗组治疗后前列腺癌患者的原发灶树突状细胞的数量明显增多,在癌及癌周均有分布,染色较深,树突状细胞亦多分布在癌周较多淋巴细胞浸润处,淋巴细胞浸润较空白组密集,CD83阳性细胞形态较空白对照组成熟,伸出伪足明显,数个叠连,染色较深。
结论
1、前列腺癌患者原发灶树突状细胞的总体数量较良性前列腺组织减少、活化受抑制。扶正抑瘤中西医治疗方案的应用能在一定治疗时段提高前列腺癌患者原发灶的树突状细胞的总体数量及活化能力。
2、中西医结合、中药针剂与汤剂联用等治疗方案在一定治疗时段显示出在提高前列腺患者树突状细胞的总体数量与活化方面的联合效应优势。
3、使用扶正抑瘤中药后,前列腺癌原发灶树突状细胞的数量增多和活化能力提高的同时能观察到局部淋巴细胞数量增加,其可能机制是树突状细胞活化后有效提呈肿瘤抗原,激活淋巴细胞,引起淋巴细胞增值,从而启动特异性细胞免疫。
Background
Prostate cancer(PCa) is one of the malignant tumors of man's reprodu ctive system.In US,the incidence of prostate cancer is listed in the fi rst place of the man's malignant tumors'.In China,its incidence has be en up rising to the 3~(rd) place of all the urinary tumors'.Most of the indi viduals were diagnosed to be prostate cancer in their later period of can cer progression.Moreover,nearly all of the patients who had received th e incretion therapy would eventually turn to be the hormone refractory ca ses.This makes it tough for Modern Medicine to cure.Urinary Surgical De partment of Guangdong Provincial Hospital of Chinese Medicine had for lon g concentrated on the study of prostate cancer,and had initially explore d its etiology,pathogenesis and syndrome differentiation.The regular pa tterns of Prostate cancer are as follows:Phase D_0:spleen Qi deficiency, kidney Qi deficiency.Phase D_1:blood stasis,lower energizer damp-heat, kidney Qi deficiency.Phase D_2:spleen Qi deficiency,blood stasis,lowe r energizer damp-heat,kidney Qi deficiency,Yin deficiency and phlegm he at,deficiency heat.Phase D_3:Qi and blood deficiency.The according int egrative treatment protocols according to TCM concept "Fuzhengyiliufa" w hich has enhancive effect of quality of life and postponement of tumor pr ogress and metestasis had later been developed,demonstrated good prospec t in clinical used.Prospective study of 142 available cases of inpatient or outpatient in Guangdong hospital of TCM from Sep.2004 to Mar.2007 h ad been conducted.The treat period was 9 months.Collected information o f Karnofsky table、weight、QLQ-C30 table、I—PSS table、ache ctassificatio n table of WHO、table for research in symptom category of prostate cancer in D period、PSA、blood testosterone、ECT of systemic bones、analysis of blood corpuscle.The remedy group is obviously better than the control group in increasing weight,improving the scale of Karnofsky table,alle viating symptoms such as tiredness、pain、insomnia、appetite losing、p ressing breach、constipation、diarrhea,improving the emotion function a nd health condition in whole;improving the symptom of lower urethra;red ucing the incidence rate of the symptom such as tiredness and fatigue,in somnia,desudation,poor appetite,difficult in urethra,pain in waist an d knee,etc.,reducing the amount of PSA and bone metastasis(P＜0.05),enh ancing the amount of blood corpuscle such as WBC、HGB、PLT in circulation. In recent clinical practice,cellular immunity function decline was seen in all prostate cancer patients.While majority of patients' cellular im munity function were seen to be enhanced after the application of "Fuzhen gyiliufa" integrative treatment.This is precisely the same goal that all immunotherapies take hope to achieve.In human immune system,specific c ellular immunity plays a key role in fighting against tumor.While dendri tic cell(DC) is deemed to be the most powerful antigen precenting cells, which is the initiator of specific immunity.However,dendritic cell-bas ed immunotherapies only manifest the transient curative effect in partial PCa patients.Since "Fuzhengyiliufa" has been observed to have effect i n immunity function,its influence in dendritic cell should be further ex plored.
Purposes
To observe the infiltration and activation of dendritic cell in prima ry foci of prostate cancer using "Fuzhengyiliufa" integrative treatments.
Methods
Perspective research,control trail,57 prostate cancer in-patients w ere intaken in the study.The first group 18 patients,who had obtained p athological specimens before and after treatments respectively,were divi ded into two subgroups,therapeutic group 10 patients,and control group 8 patients.The therapeutic group received "Fuzhengyiliufa" integrative t reatment("Fuzhengyiliufa" TCM treatments combined with routine incretion therapy),the control group receieved routine incretion therapy,and the therapeutic period ranged between 7 days to 105 days.The second group 3 9 patients,who had only obtained 1 pathological specimen in each,were d ivided into two subgroups according to whether patients received "Fuzheng yiliufa" TCM treatment or not before their biopsy:therapeutic group 19 pa tients;blank control group 20 patients.The therapeutic group received "Fuzhengyiliufa" TCM treatments,the therapeutic period ranged between 7 to 25 days,8.7 days in average;control group didin't received any trea tment,then marked the CD1a positive dendritic cell and the CD83 positive dendritic cell which infiltrated in these pathological sections with the immunohistochemistry technique of "Envision" two step staining,and rec orded the quantities of these dendritc cells with microscope.The negativ e ones would be recorded as "0" in quatity.As for statistics analysis, dependent t-test would be used to compare means of dependent groups if th e variance meets Gaussion distribution,if not,non-parametric test(Mann -Whitney Test) would be applied,p＜0.05 has the significance for the diff erence.Pair groups t-test would be used to compare means of pair groups if the variance meets Gaussion distribution,if not,non-parametric test (Wilcoxon Test) would be applied,p＜0.05 has the significance for the dif ference.Statistic analysis software SPSS13.0 would be applied.
Results
1.The first group 18 patients who had obtained twice pathologic samp les in each,therapeutic subgroup 10 patients,with 1 before treatment sa mple CDla negative and 1 before treatment sample CD83 negative;Control s ubgroup 8 patients,with 1 after treatment sample CD1a negative and 1 aft er treatment sample CD83 negative.The quantity of CD1a positive DC after treatment in both groups elevated compared to the quantity of CD1a befor e treatments,the differences had statistical significance.The quantity of CD83 positive DC after treatment in therapeutic group elevated compare d to the quantity of CD83 positive DC before treatment,the differences h ad statistical significance,P≤0.05.The quantity of CD83 positive DC af ter treatment in control group elevated compared to the quantity of CD83 positive DC before treatment,the differences had no statistical signific ance,P＞0.05.The quantity difference of CD1a positive DC of therapeutic group were more than the ones of control group,the differences had no st atistical significance,P＞0.05.The quantity differences of CD83 positive DC of therapeutic group were more than the ones of control group,the di fferences had statistical significance,P＜0.05.
2.The second group 39 patients,who had obtained one pathologic samp le,therapeutic group 19 patients,with 1 sample CD1a negative;blank con trol group 20 patients,with 3 sample CD1a negative and 2 sample CD83 neg ative.The quantity of CD1a positive DC in therapeutic group surpass blan k control group,the difference had statistical significance,P＜0.05.The quantity of CD83 positive DC in therapeutic group surpass blank control group,the difference had statistical significance,P＜0.05.
3.Single use of "Fuzhengyiliufa" Chinese Medicine group elevated CD8 3 in quantity compared to blank control group,the differernce had statis tical significance,P＜0.05.
4.In descriptive study of comparision of various "Fuzhengyiliufa" tr eatments,it could be seen that the CD1a、CD83 elevating effect of conbine d used of herbal decortions and herbal injections were better than single use of herbal decortion,the differences had statistical significance,P＜0.05.
5.It could be observed with microscope in blank control group PCa pa tients' pathological section that the infiltrated dendritic cell declined in quatity and disfunction in activating.Marked by CD1a and CD83,dendr itic cells were stained in their cytoplasmid and nuclear,appeared immatu re in shape that less like dendritic form.Their staining is lighter than the ones in benign hyperplasia tissues,with prominent decline in CD83. Dendritic cell infiltration is more concentrating in mesenchrymal tissues beside tumor tissue with infiltrated lymphocyte arround.In therapeutic group PCa patients' pathological sections,infiltrated dendritic cell are much more in quantity.Dendritic cell infiltration is more concentrating, not only in mesenchrymal tissues but also in between the tumor cells.Th ey appeared more mature in dendritic form,staining darker.Moreover,the dendritic cells,marked by CD83,are more mature in shape with more conc entrating infiltrated lymphocytes around.
Conclusions
1.Infiltrated dendritic cells in prostate cancer primary foci were l ess than the ones in benign hyperplasia tissues in quantity.Their activa tion was inhibited.The application of "Fuzhengyiliufafa" integrative tr eatment protocol could increase the quantity of dendritic cell in prostat e cancer primary foci and greatly enhance their activating ability in cer tain therapeutic period.
2.It could be seen that the DC quantity elevating effect and the DC activation reinforcement effect of integrative therapy of Chinese Medicin e and incretion therapy and the combination of herbal decortions and inje ctions had advantage over other single used treatments.
3.It could be observed that with the elevated quantity and activatin g ability of dendritic cell,local lymphocytes infiltration became more c oncentrating.The probable mechanism was that activating dendritic cells precent tumor antigens to activate T lymphocytes.That leads to prolifera tion and expansion of T lymphocyte.In that way specific immunity was ini tiated.
引文
[1]吕立国,陈志强,王树声,等.中西医结合扶正抑瘤法治疗前列腺癌142例临床观察[J].新中医.2008(001):26-27.
[2]Thomas-kaskel A K,Waller C F,Schultze-seemann W,et al.Immunotherapy with dendritic cells for prostate cancer[J].International Journal of Cancer.2007,121(3).
[3]Slovin S F.Immunologic targeting:how to channel a minimal response for maximal outcome.[J].Current Opinion in Urology.2006,16(3):179.
[4]Miller A M,Pisa P.Tumor escape mechanisms in prostate cancer[J].Cancer Immunology,Immunotherapy.2007,56(1):81-87.
[5]韩超峰,曹雪涛.肿瘤诱导的树突状细胞功能缺陷及其机制[J].中国肿瘤生物治疗杂志.2005,12(002):89-93.
[6]Groux H,Cottrez F,Rouleau M,et al.A Transgenic Model to Analyze the Immunoregulatory Role of IL-10 Secreted by Antigen-Presenting Cells 1[J].The Journal of Immunology.1999,162(3):1723-1729.
[7]Salazar-onfray F.Interleukin-10:a cytokine used by tumors to escape immunosurveillance[J].Cancer Immunology,Immunotherapy.1999,16(2):86-94.
[8]Allavena P,Piemonti L,Longoni D,et al.IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages[J].European Journal of Immunology.1998,28(1).
[9]张毅,陈磐.转化生长因子β1对鼠造血祖细胞产生树突状细胞的调控作用[J].中华医学杂志.1999,79(003):178-180.
[10]Chang C H,Guerder S,Hong S C,et al.Mice lacking the MHC class Ⅱtransactivator(CIITA) show tissue-specific impairment of MHC class Ⅱexpression.[J].Immunity.1996,4(2):167.
[11]Wahl S M.Transforming growth factor-beta is a potent immunosuppressive agent that inhibits IL-1-dependent lymphocyte proliferation[J].The Journal of Immunology.1988,140(9):3026-3032.
[12]Zou W.Immunosuppressive networks in the tumour environment and their therapeutic relevance[J].Nature Reviews Cancer.2005,5(4):263-274.
[13]Baratelli F E,Heuze-vourc N,Krysan K,et al.Prostaglandin E2-Dependent Enhancement of Tissue Inhibitors of Metalloproteinases-1 Production Limits Dendritic Cell Migration through Extracellular Matrix 1[J].The Journal of Immunology.2004,173(9):5458-5466.
[14]Zhang X M,Xu Q.Metastatic melanoma cells escape from immunosurveillance through the novel mechanism of releasing nitric oxide to induce dysfunction of immunocytes.[J].Melanoma Research.2001,11(6):559.
[15]Moller P,Koretz K,Leithauser F,et al.Expression of APO-1(CD95),a member of the NGF/TNF receptor superfamily,in normal and neoplastic colon epithelium[J].International Journal of Cancer.1994,57(3).
[16]Gabrilovich D I,Cheng P,Fan Y,et al.H1(0) histone and differentiation of dendritic cells.Amolecular target for tumor-derived factors.[J].Journal of leukocyte biology.2002,72(2):285.
[17]荆雪宁,张玲.CD44与肿瘤的免疫逃逸[J].国外医学:肿瘤学分册.2004,31(003):186-189.
[18]Troy A,Davidson P,Atkinson C,et al.Phenotypic characterisation of the dendritic cell infiltrate in prostate cancer[J].The Journal of Urology.1998,160(1):214-219.
[19]Gabrilovich D.Mechanisms and functional significance of tumour-induced dendritic-cell defects[J].Nature Reviews Immunology.2004,4(12):941-952.
[20]Midis G P.Elevated soluble Fas(sFas) levels in nonhematopoietic human malignancy[J].Cancer Research.1996,56(17):3870-3874.
[21]李博.以树突状细胞为基础的前列腺癌免疫治疗[J].国外医学:泌尿系统分册.2003,23(003):237-240.
[22]Mimura K,Kono K,Takahashi A,et al.Vascular endothelial growth factor inhibits the function of human mature dendritic cells mediated by VEGF receptor-2[J].Cancer Immunology,Immunotherapy.2007,56(6):761-770.
[23]Brandacher G,Perathoner A,Ladurner R,et al.Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer:effect on tumor-infiltrating T cells[Z].AACR,2006:12,1144-1151.
[24]Hou D Y,Muller A J,Sharma M D,et al.Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses[J].Cancer research.2007,67(2):792.
[25]Kim R,Emi M,Tanabe K.Functional roles of immature dendritic cells in impaired immunity of solid tumour and their targeted strategies for provoking tumour immunity[J].Clinical and Experimental Immunology.2006,146(2):189.
[26]Ghiringhelli F,Puig P E,Roux S,et al.Tumor cells convert immature myeloid dendritic cells into TGF-{beta}-secreting cells inducing CD4+ CD25+regulatory T cell proliferation[J].Journal of Experimental Medicine.2005, 202(7):919.
[27]Hideo H,Takahiro H,Hiroaki Y.Compartmental imbalance and aberrant immune function of blood CD123(plasmacytoid) and CDlle(myeloid) dendritic cells in atopic dermatitis[J].J Immumol.2005,174(4):2396-2403.
[28]Zou W,Machelon V,Coulomb-1H A,et al.Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells[J].Nature medicine.2001,7:1339-1346.
[29]Curiel r J,Wei S,Dong H,et al.Blockade of B7-H1 improves myeloid dendritic cell? mediated antitumor immunity[J].Nature Medicine.2003,9:562-567.
[30]Curiel T J,Cheng P,Mottram P,et al.Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer[Z].AACR,2004:64,5535-5538.
[31]齐士勇,王萌,徐勇.前列腺癌组织中树突状细胞的变化及以此为基础的免疫治疗[J].中华男科学杂志.2007,13(5).
[32]Shurin G V,Aalamian M,Pirtskhalaishvili G,et al.Human prostate cancer blocks the generation of dendritic cells from CD34+ hematopoietic progenitors[J].European urology.2001,39:37-40.
[33]Aalamian M,Pirtskhalaishvili G,Nunez A,et al.Human prostate cancer regulates generation and maturation of monocyte-derived dendritic cells[J].The Prostate.2001,46(1).
[34]Pirtskhalaishvili G,Shurin G V,Esche C,et al.Cytokine-mediated protection of human dendritic cells from prostate cancer-induced apoptosis is regulated by the Bcl-2 family of proteins[J].British Journal of Cancer.2000,83:506-513.
[35]Gabrilovich D I.Decreased antigen presentation by dendritic cells in patients with breast cancer[J].Clinical Cancer Research.1997,3(3):483-490.
[36]Bonifaz L,Bonnyay D,Mahnke K.Efficient targeting of protein antigen to the dendritic cell receptor DEC 2 205 in the steady state leads to antigen presentation on major histocompatibility complex class Iprod 2 ucts and peripheral CD8+ T cell tolerance[J].J Exp Med.2002,196(12):627-1638.
[37]Shurin M R,Lu L,Ka]inski P,et al.Th1/Th2 balance in cancer,transplantation and pregnancy[C].Springer,1999.
[38]Ho C S,Lopez J A,Vuckovic S,et al.Surgical and physical stress increases circulating blood dendritic cell counts independently of monocyte counts[J]. Blood.2001,98(1):140.
[39]Burch P A,Breen J K,Buckner J C,et al.Priming Tissue-specific Cellular immunity in a Phase I Trial of Autologous Dendritic Cells for Prostate Cancer 1[Z].AACR,2000:6,2175-2182.
[40]Alessandro S,Miriam L,Annamaria A O,et al.Characterization of circulating blood dendritic cell subsets DC123+(Lymphoid) and DC11C+(myeloid)in prostate adenocarcinoma patients[J].The Prostate.2007,67(1).
[41]Harzstark A L,Small E J.Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells:APC8015(ProvengeR)[J].Expert Opinion on Biological Therapy.2007,7(8):1275-1280.
[42]李绍杰.激素难治性前列腺癌治疗进展[J].老年医学与保健.2007,13(006):389-392.
[43]Triozzi P L,Khurram R,Aldrich W A,et al.Intratumoral injection of dendritic cells derived in vitro in patients with metastatic cancer[J].Cancer.2000.89(12).
[44]张晓光,徐勇.前列腺癌免疫治疗的进展[J].国外医学:泌尿系统分册.2004,24(002):172-177.
[45]Tarassoff C P,Arlen P M,Gulley J L.Therapeutic vaccines for prostate cancer[J].The Oncologist.2006,11(5):451-462.
[46]Fong L,Brockstedt D,Benike C,et al.Dendritic Cell-Based Xenoantigen Vaccination for Prostate Cancer Immunotherapy 1[J].The Journal of Immunology.2001,167(12):7150-7156.
[47]Small E J,Fratesi P,Reese D M,et al.Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells[J].Journal of Clinical Oncology.2000,18(23):3894.
[48]Murphy G,Tjoa B,Ragde H,et al.Phase I clinical trial:T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen[J].The Prostate.1996,29(6).
[49]Tjoa B A,Lodge P A,Salgaller M L,et al.Dendritic cell-based immunotherapy for prostate cancer[J].CA:A Cancer Journal for Clinicians.1999,49(2):117-128.
[50]Heiser A,Coleman D,Dannull J,et al.Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors[J].Journal of Clinical Investigation. 2002,109(3):409-417.
[51]Vonderheide R H,Domchek S M,Schultze J L,et al.Vaccination of cancer patients against telomerase induces functional antitumor CDS+ T lymphocytes[Z].AACR,2004:10,828-839.
[52]Mu L J,Kyte J A,Rvalheim G,eL al.Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients[J].British journal of cancer.2005,93:749-756.
[53]Su Z,Dannull J,Yang B K,et at.Telomerase mRNA-Transfected Dendritic Cells Stimulate Antigen-Specific CD8+ and CD4+ T Cell Responses in Patients with Metastatic Prostate Cancer 1[J].The Journal of Immunology.2005,174(6):3798-3807.
[54]Ribas A.Genetically modified dendritic cells for cancer immunotherapy[J].Current gene therapy.2005,5:619-628.
[55]覃汉军,张叔人.前列腺癌的免疫基因治疗研究进展[J].中国免疫学杂志.2005.8.
[56]Craft N,Chhor C,Tran C,et al.Evidence for Clonal Outgrowth of Androgen-independent Prostate Cancer Cells from Androgen-dependent Tumors through a Two-Step Process 1[Z].AACR,1999:59,5030-5036.
[57]陈朝晖,肖传国.雄激素受体异常激活与激素非依赖性前列腺癌的形成机制[J].医学分子生物学杂志.2004,1(005):309-312.
[58]Weidner N,Carroll P R,Flax J,et al.Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma.[J].The American Journal of Pathology.1993,143(2):401.
[59]刘秋英,王一飞.血管生成及其抑制剂在前列腺癌中的研究进展[J].中国病理生理杂志.2004,20(012):2347-2352.
[60]Carlson R W,Anderson B O,Burstein H J.NCCN Clinical Practice Guidelines in Oncology[J].Breast Cancer.2006.
[61]那彦群.中国泌尿外科疾病诊断治疗指南[Z].北京:人民卫生出版社,2006.
[62]Han K R,Seligson D B,LiuX,et al.Prostate stem cell antigen expression is associated with gleason score,seminal vesicle invasion and capsular invasion in prostate cancer[J].The Journal of Urology.2004,171(3):1117-1121.
[63]Ross S,Spencer S D,Holcomb I,et al.Prostate Stem Cell Antigen as Therapy Target Tissue Expression and in Vivo Efficacy of an Immunoconjugate[Z].AACR,2002:62,2546-2553.
[64]许传亮,顾正勤,孙颖浩,等.抗人前列腺干细胞抗原单克隆抗体的前列腺癌免疫病理研究[J].上海医学.2005,28(005):363-365.
[65]姜涛,姜辉,宋希双,等.前列腺癌中P53的表达及其临床意义[J].中华男科学杂志.2005,11(006):448-451.
[66]Singh H,Canto E I,Shariat S F,et al.Improved detection of clinically significant,curable prostate cancer with systematic 12-core biopsy[J].The Journal of Urology.2004,171(3):1089-1092.
[67]史密斯.泌尿外科学[Z].北京:人民卫生出版社,2005.
[68]肖芹,印洪林,陆珍凤,等.前列腺癌G1eason分级评分与血清PSA,原位PSA的变化和34βE12,P504S免疫表型的研究[J].中华男科学杂志.2004,10(005):362-365.
[69]Carroll P R.Normograms are superior to staging and risk grouping systems for identifying high-risk patients:preoperative application in prostate cancer[J].Urol ONcol.2003,21(6):484-485.
[70]Oh W K.The evolving role of estrogen therapy in prostate cancer[J].Clinical Genitourinary Cancer.2002,1(2):81-89.
[71]李汉忠,严维刚.前列腺癌近距离治疗的研究进展[J].中华外科杂志.2005,43(002):129-131.
[72]叶敏.前列腺癌的间歇雄激素了阻断疗法(附编者按)[J].中华泌尿外科杂志.2001,22(002):116-118.
[73]徐勇刚,李高峰.前列腺癌的放射治疗进展[J].中华老年医学杂志.2006,25(001):68-70.
[74]Saad F,Guise T,Hussain A,et al.The role of intravenous bisphosphonates in the management of prostate cancer:treatment guidelines[J].Am J Urol Rev.2004,2(suppl 2):9-15.
[75]楚延春,张同斌.前列腺癌的病因病机浅探[J].河南中医药学刊.1997,12(004):14-16.
[76]彭煜,彭培初.泉安方治疗晚期前列腺癌骨转移痛初探(附18例报告)[J].中国男科学杂志.2004,18(004):46-48.
[77]李恒山,杨玉霞.中医药治疗晚期前列腺癌12例报告[J].四川中医.2004,22(005):48-48.
[78]吕立国,古炽明,王昭辉,等.陈志强教授对晚期前列腺癌中医病因病机的探讨[J].新中医.2007,39(002):81-82.
[79]张剑.李辅仁治疗前列腺癌睾丸摘除术后诸症的经验[J].中医杂志.1998,39(002):83-83.
[80]厉将斌,王沛.前列腺癌中医药治疗的经验与思路[J].中国中西医结合杂志.2002,22(006):425-425.
[81]丁永锋,张亚大,朱子军,等.77例前列腺癌中医证型特点与临床相关因素分析[J].中国中西医结合外科杂志.2006,12(006):528-530.
[82]朱晓光.晚期前列腺癌的中医药治疗现状[J].现代中西医结合杂志.2006,15(011):1552-1553.
[83]吕立国,代睿欣,王昭辉,等.陈志强教授扶正抑瘤法治疗晚期前列腺癌临床经验介绍[J].新中医.2007,39(005):91-92.
[84]陈佑邦.中华人民共和国中医药行业标准——中医病证诊断疗效标准[Z].南京:南京大学出版社,1994.
[85]Wang R G,You Z L,Feng G R.Study on the plant estrogen in Chinese herbal medicine[J].Zhongguo Zhong Xi Yi Jie He Za Zhi.2004,24(2):169-171.
[86]宋丽华.植物性雌激素的研究进展[J].国外医学:药学分册.2003,30(001):25-29.
[87]Rosenberg Z R,Jenkins D J,Brown T J,et al.Flavonoids can block PSA production by breast and prostate cancer cell lines[J].Clinica chimicaacta.2002,317(1-2):17-26.
[88]魏道智,郭澄,刘皋林.抗癌中药中微量元素与抗癌活性的相关性[J].中国医学生物技术应用杂志.2003,12(8):12-19.
[89]钱韵旭,赵浩如,高展.白花蛇舌草提取物的体外抗肿瘤活性[J].江苏药学与临床研究.2004,12(004):36-38.
[90]王宇翎,张艳,方明,等.白花蛇舌草总黄酮的免疫调节作用[J].中国药理学通报.2005,21(004):444-447.
[91]于春艳,李薇,刘玉和,等.白花蛇舌草提取物体外抗肿瘤作用及机制研究[J].北华大学学报:自然科学版.2004,5(005):412-416.
[92]谭永红.中药半枝莲的研究进展[J].西南国防医药.2002(02).
[93]庞雅琴,罗琼,李卓能,等1.番茄汁对人前列腺癌细胞DNA损伤作用的影响[J].中国公共卫生.2005,21(001):37-38.
[94]Agarwal R,Wang Z Y,Mukhtar H.Inhibition of mouse skin tumor-initiating activity of DMBA by chronic oral feeding of glycyrrhizin in drinking water[J].Nutr Cancer.1991,15(3-4):187-193.
[95]Lee S C,Kuan C Y,Yang C C,et al.Bioflavonoids commonly and potently induce tyrosine dephosphorylation/inactivation of oncogenic proline-directed protein kinase FA in human prostate carcinoma cells.[J].Anticancer research.1998,18(2A):1117.
[96]张红.女贞子的药理作用研究状况[J].时珍困药研究.1997,8(003):275-276.
[97]黄镜,孙燕.熊果酸的抗肿瘤活性[J].中国新药杂志.1997,6(002):101-104.
[98]陈朝晖,赵军,肖亚军,等.姜黄素诱导人前列腺癌细胞株PC-3凋亡的研究[J].中华实验外科杂志.2005,22(004):507-507.
[99]魏道智,郭澄.中药蝼蛄中微量元素与临床药效的相关性分析[J].广东微量元素科学.2002,9(010):64-67.
[100]顾正勤,孙颖浩,许传亮,等.黄芩苷诱导前列腺癌细胞株DU145凋亡的体外研究[J].中国中药杂志.2005,30(001):63-66.
[101]谌科,胡志全,叶章群.姜黄素和顺铂联用对雄激素非依赖性前列腺癌细胞PC-3作用[J].中国医院药学杂志.2005,25(006):542-544.
[102]刘雪莉,孙静芸.枸杞子抑制人前列腺细胞增殖活性成分的提取与分离[J].中国中药杂志.2000,25(008):481-483.
[103]Darzynkiewicz Z,Traganos F,Wu J M,et al.Chinese herbal mixture PC SPES in treatment of prostate cancer(review)[J].International Journal of Oncology.2000,17(4):729-736.
[104]张群豪,陈可冀.美国PC—SPES(中药复方)抗前列腺癌进展续报[J].中国中西医结合杂志.2002,22(4):297-297.
[105]师长进,俞莉章,那彦群,等.中药紫龙金对转移性前列腺癌体外增殖及侵袭能力的影响[J].中华外科杂志.2003,41(006):473-473.
[106]杜广,郭鹏,郭剑明,等.德士康对前列腺癌激素非依赖型细胞株细胞周期的抑制作用[J].肿瘤.2005,25(002):136-139.
[107]Giordano F J,Johnson R S.Angiogenesis:the role of the microenvironment in flipping the switch[J].Current Opinion in Genetics & Development.2001,11(1):35-40.
[108]Dotal T,Cao Y C,Dorai B,et al.Therapeutic Potentialof Curcuminin Human Prostate Cancer.Ⅲ.Curcumin Inhibits Proliferation,Induces Apoptosis,and Inhibits Angiogenesisof LNCaPProstate Cancer Cells InVivo[J].The Prostate.2001,47:293-303.
[109]王毅,郝钰,邱全瑛,等.人参皂苷Rg1,Rh1对树突状细胞刺激T细胞增殖及LPAK抗肿瘤活性的影响[J].中国免疫学杂志.2003,19(004):248-252.
[110]Vermeiren J,Ceuppens J L,Van G M,et al.Human T Cell Activation by Costimulatory Signal-Deficient Allogeneic Cells Induces Inducible Costimulator-Expressing Anergic T Cells with Regulatory Cell Activity 1[J]. The Journal of Immunology.2004,172(9):5371-5378.
[111]张印,郭建刚.中药保元丹对肺癌患者化疗后T淋巴细胞功能的影响[J].第四军医大学学报.2005,25(13).
[112]李道明.中药对辅助化疗患者免疫功能的影响[J].湖北中医杂志.2005,27(009):44-44.
[113]陈学林,袁杰,刘承云,等.参芪扶正注射液配合化疗改善老年消化道肿瘤48例机体状况的观察[J].陕西中医.2006,27(003):287-288.
[114]吴皓,林洪生,裴迎霞,等.人参皂甙Rg3对荷瘤及环磷酰胺化疗小鼠黏膜免疫力影响[J].中国肿瘤.2006,15(006):369-371.
[115]Kushibiki T,Matsumoto K,Nakamura T,et al.Suppression of tumor metastasis by NK4 plasmid DNA released from cationized gelatin[J].Gene therapy.2004,11(15):1205-1214.
[116]周昌艳,唐庆九,杨焱,等.灵芝中有效成分灵芝酸的抑制肿瘤作用研究[J].菌物学报.2004,23(002):275-279.
[117]宁安红,曹婧,黄敏,等.灵芝多糖对荷瘤小鼠肿瘤免疫系统的影响[J].中国微生态学杂志.2004,16(001):13-14.
[118]李泽庚,张杰根,彭波,等.肺气虚证和肺阴虚证患者外周血NK细胞表达分析[J].中医杂志.2005,46(007):533-534.
[119]赵丽红,徐蔚杰.正得康对非小细胞肺癌患者扶正作用的临床观察[J].实用中西医结合临床.2004,4(004):23-23.
[120]刘海涛,戴锡孟.中药扶正合剂对LA795转移性肺癌小鼠的抑瘤作用和机制研究[J].江苏中医药.2004,25(010):56-58.
[121]冯磊,寿春晖,冯永生,等.中药扶正配方在消化道肿瘤治疗中的作用[J].浙江中西医结合杂志.2006,16(005):272-274.
[122]朱小东,王安宇,王绍丰,等.中药扶正抗癌胶囊2号对荷瘤小鼠的免疫效应[J].中国肿瘤临床与康复.2003,10(006):517-518.
[123]李杰,宋淑霞,韩丽枝,等.益气补肾方药对化疗荷瘤小鼠免疫功能的影响[J].中国实验动物学报.2004,12(003):152-155.
[124]汪永锋,张延英,李广远,等.贞芪酪蛋白复合肽对大鼠巨噬细胞功能的调节作用[J].中医研究.2006,19(003):22-24.
[125]毕明星,刘作金,王华丽,等.肝癌-1号对大鼠巨噬细胞杀伤肝癌细胞能力的影响及机制[J].世界华人消化杂志.2006,14(005):526-529.
[126]Reome J B,Hylind J C,Dutton R W,et al.Type 1 and type 2 tumor infiltrating effector cell subpopulations in progressive breast cancer[J].Clinical Immunology.2004,111(1):69-81.
[127]Hsiao Y W,Liao K W,Hung S W,et al.Tumor-Infiltrating Lymphocyte Secretion of IL-6 Antagonizes Tumor-Derived TGF-β1 and Restores the Lymphokine-Activated Killing Activity 1[J].The Journal of Immunology.2004,172(3):1508-1514.
[128]黄立中,伍参荣,王云启,等.益气平悬饮提取物对肺癌胸水中肿瘤浸润淋巴细胞杀伤活性的影响[J].中医药学刊.2004,22(002):230-232.
[129]吴良村,陈良良,李庆霞,等.康莱特对肿瘤浸润淋巴细胞的体外扩增及抗肿瘤作用的研究[J].中国医药学报.2004,19(011):656-658.
[130]张宏方,马振亚,胥冰,等.中药调衡方对S180与H22荷瘤小鼠TNF与LAK细胞活性的影响[J].陕西中医.2005,26(009):983-985.
[131]席亚明,王镜.梁金菇多糖对荷瘤鼠的抗肿瘤作用和免疫功能影响[J].华西医学.2005,20(001):43-44.
[132]刘丽宏,单保恩,刁兰萍,等.参芪扶正注射液对血液系统恶性肿瘤患者红细胞免疫功能的影响[J].浙江中医杂志.2003,38(012):542-542.
[133]李雪峰,赵健雄.扶正抑瘤颗粒对食管癌放疗患者红细胞免疫功能的影响[J].上海中医药杂志.2004,38(007):51-52.
[134]陈德轩,潘立群.术后应用爱迪注射液对食管癌红细胞免疫影响的临床研究[J].东南大学学报:医学版.2004,23(002):117-119.
[135]任为,王又红.芪瑞扶正胶囊对免疫抑制小鼠红细胞免疫的影响[J].山东中医杂志.2004,23(001):36-38.
[136]查占山,钱宝华,郭峰,等.红细胞CD35在抗原激活淋巴细胞免疫反应中的作用[J].解放军医学杂志.2006,31(002):104-105.
[137]王运田,单保思,李巧霞.黄芪提取物免疫调节活性的体外研究[J][J].中国中西医结合杂志.2002,22(6):453-455.
[138]付于,夏天.消瘤汤治疗肿瘤及调节免疫功能的实验研究[J].中国中西医结合杂志.2004,24(012):1114-1117.
[139]李益民,张瑛.参希胶囊对肿瘤患者细胞免疫功能的影响[J].国医论坛.2004,19(002):21-22.
[140]薛兴奎,张玲,王芸,等.ICA,PJA逆转人高转移肺癌细胞Fas/FasL途径免疫逃逸机制的研究[J].中国免疫学杂志.2004,20(002):102-105.
[141]赵健雄,朱玉真,沈世林,等.扶正抑瘤颗粒对荷瘤(H22)小鼠T淋巴细胞Fas/FasL蛋白表达的影响[J].中国中医药科技.2006,13(001):14-15.
[142]崔澂,王润田.TGF-β介导的肿瘤免疫抑制研究及临床意义[J].实用肿瘤杂志.2005,5.
[143]何彦丽,应逸,罗荣敬,等.枸杞多糖对荷瘤小鼠免疫抑制因子VEGF,TGF- β1水平的影响[J].中药新药与临床药理.2005,16(003):172-174.
[144]王薇,李萍萍.中药影响树突状细胞抗肿瘤免疫作用的研究进展[J].临床肿瘤学杂志.2007,8.
[145]邵鹏,赵鲁杭.黄芪多糖对树突状细胞表型及功能成熟的影响[J].中华微生物学和免疫学杂志.2006,26(007):637-640.
[146]邓曼,窦晓兵,史亦谦,等.黄芪多糖体外诱导脐血单核细胞分化为树突状细胞及其免疫学特征[J].医学研究杂志.2006,35(009):22-26.
[147]董静,顾华丽,马承泰,等.大剂量黄芪对急性白血病患儿外周血树突状细胞的诱导和抗原呈递功能的影响[J].中国中西医结合杂志.2005,25(010):872-875.
[148]董竞成,董晓辉.黄芪注射液与白细胞介素2增强树突细胞抗肿瘤转移作用的比较研究[J].中国中西医结合杂志.2005,25(003):236-239.
[149]林志彬.灵芝抗肿瘤活性和免疫调节作用的研究进展[J].北京大学学报:医学版.2002,34(005):493-498.
[150]孙丽华,赵明耀,黄幼田,等.灵芝孢子粉对荷瘤小鼠树突状细胞的影响及其抗瘤效应[J].山西医药杂志.2006,35(008):698-700.
[151]王毅,郝钰,邱全瑛,等.人参皂苷Rg1,Rh1对树突状细胞刺激T细胞增殖及LPAK抗肿瘤活性的影响[J].中国免疫学杂志.2003,19(004):248-252.
[152]方美云,王忠裕,王一.细胞因子联合人参皂甙及三氧化二砷诱导HL-60细胞向树突状细胞分化的实验研究[J].实用癌症杂志.2005,20(001):15-19.
[153]朱杰,赵鲁杭,陈智.枸杞多糖对小鼠骨髓树突状细胞成熟的影响[J].浙江大学学报:医学版.2006,35(006):648-652.
[154]荣微,井欢,刘春英.香菇多糖对荷瘤小鼠树突状细胞功能影响的实验研究[J].中医药学刊.2006,24(004):681-682.
[155]侯安继,杨占秋,黄菁,等.羧甲基茯苓多糖上调HBV转基因小鼠树突状细胞功能[J].武汉大学学报:理学版.2006,52(006):778-782.
[156]郭文菁,杨美香,曲迅,等.罗勒多糖对树突状细胞表面分子表达的影响[J].中国免疫学杂志.2006,22(009):827-829.
[157]杜桂清,孙光,郭连英,等.榄香烯复合瘤苗冲激的树突状细胞的功能研究[J].中国肿瘤生物治疗杂志.2005,12(004):295-297.
[158]陈智超,王红祥,游泳,等.参芪扶正注射液对急性髓系白血病患者树突状细胞作用的体外研究[J].临床内科杂志.2007,24(007):455-457.
[159]杨莉,李艳佳,刘京生,等.复方中药对外周血树突状细胞的干预作用[J].细胞与分子免疫学杂志.2007,23(007):606-608.
[2]Thomas-kaskel A K,Waller C F,Schultze-seemann W,et al.Immunotherapy with dendritic cells for prostate cancer[J].International Journal of Cancer.2007,121(3).
[3]Slovin S F.Immunologic targeting:how to channel a minimal response for maximal outcome.[J].Current Opinion in Urology.2006,16(3):179.
[4]Miller A M,Pisa P.Tumor escape mechanisms in prostate cancer[J].Cancer Immunology,Immunotherapy.2007,56(1):81-87.
[5]韩超峰,曹雪涛.肿瘤诱导的树突状细胞功能缺陷及其机制[J].中国肿瘤生物治疗杂志.2005,12(002):89-93.
[6]Groux H,Cottrez F,Rouleau M,et al.A Transgenic Model to Analyze the Immunoregulatory Role of IL-10 Secreted by Antigen-Presenting Cells 1[J].The Journal of Immunology.1999,162(3):1723-1729.
[7]Salazar-onfray F.Interleukin-10:a cytokine used by tumors to escape immunosurveillance[J].Cancer Immunology,Immunotherapy.1999,16(2):86-94.
[8]Allavena P,Piemonti L,Longoni D,et al.IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages[J].European Journal of Immunology.1998,28(1).
[9]张毅,陈磐.转化生长因子β1对鼠造血祖细胞产生树突状细胞的调控作用[J].中华医学杂志.1999,79(003):178-180.
[10]Chang C H,Guerder S,Hong S C,et al.Mice lacking the MHC class Ⅱtransactivator(CIITA) show tissue-specific impairment of MHC class Ⅱexpression.[J].Immunity.1996,4(2):167.
[11]Wahl S M.Transforming growth factor-beta is a potent immunosuppressive agent that inhibits IL-1-dependent lymphocyte proliferation[J].The Journal of Immunology.1988,140(9):3026-3032.
[12]Zou W.Immunosuppressive networks in the tumour environment and their therapeutic relevance[J].Nature Reviews Cancer.2005,5(4):263-274.
[13]Baratelli F E,Heuze-vourc N,Krysan K,et al.Prostaglandin E2-Dependent Enhancement of Tissue Inhibitors of Metalloproteinases-1 Production Limits Dendritic Cell Migration through Extracellular Matrix 1[J].The Journal of Immunology.2004,173(9):5458-5466.
[14]Zhang X M,Xu Q.Metastatic melanoma cells escape from immunosurveillance through the novel mechanism of releasing nitric oxide to induce dysfunction of immunocytes.[J].Melanoma Research.2001,11(6):559.
[15]Moller P,Koretz K,Leithauser F,et al.Expression of APO-1(CD95),a member of the NGF/TNF receptor superfamily,in normal and neoplastic colon epithelium[J].International Journal of Cancer.1994,57(3).
[16]Gabrilovich D I,Cheng P,Fan Y,et al.H1(0) histone and differentiation of dendritic cells.Amolecular target for tumor-derived factors.[J].Journal of leukocyte biology.2002,72(2):285.
[17]荆雪宁,张玲.CD44与肿瘤的免疫逃逸[J].国外医学:肿瘤学分册.2004,31(003):186-189.
[18]Troy A,Davidson P,Atkinson C,et al.Phenotypic characterisation of the dendritic cell infiltrate in prostate cancer[J].The Journal of Urology.1998,160(1):214-219.
[19]Gabrilovich D.Mechanisms and functional significance of tumour-induced dendritic-cell defects[J].Nature Reviews Immunology.2004,4(12):941-952.
[20]Midis G P.Elevated soluble Fas(sFas) levels in nonhematopoietic human malignancy[J].Cancer Research.1996,56(17):3870-3874.
[21]李博.以树突状细胞为基础的前列腺癌免疫治疗[J].国外医学:泌尿系统分册.2003,23(003):237-240.
[22]Mimura K,Kono K,Takahashi A,et al.Vascular endothelial growth factor inhibits the function of human mature dendritic cells mediated by VEGF receptor-2[J].Cancer Immunology,Immunotherapy.2007,56(6):761-770.
[23]Brandacher G,Perathoner A,Ladurner R,et al.Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer:effect on tumor-infiltrating T cells[Z].AACR,2006:12,1144-1151.
[24]Hou D Y,Muller A J,Sharma M D,et al.Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses[J].Cancer research.2007,67(2):792.
[25]Kim R,Emi M,Tanabe K.Functional roles of immature dendritic cells in impaired immunity of solid tumour and their targeted strategies for provoking tumour immunity[J].Clinical and Experimental Immunology.2006,146(2):189.
[26]Ghiringhelli F,Puig P E,Roux S,et al.Tumor cells convert immature myeloid dendritic cells into TGF-{beta}-secreting cells inducing CD4+ CD25+regulatory T cell proliferation[J].Journal of Experimental Medicine.2005, 202(7):919.
[27]Hideo H,Takahiro H,Hiroaki Y.Compartmental imbalance and aberrant immune function of blood CD123(plasmacytoid) and CDlle(myeloid) dendritic cells in atopic dermatitis[J].J Immumol.2005,174(4):2396-2403.
[28]Zou W,Machelon V,Coulomb-1H A,et al.Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells[J].Nature medicine.2001,7:1339-1346.
[29]Curiel r J,Wei S,Dong H,et al.Blockade of B7-H1 improves myeloid dendritic cell? mediated antitumor immunity[J].Nature Medicine.2003,9:562-567.
[30]Curiel T J,Cheng P,Mottram P,et al.Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer[Z].AACR,2004:64,5535-5538.
[31]齐士勇,王萌,徐勇.前列腺癌组织中树突状细胞的变化及以此为基础的免疫治疗[J].中华男科学杂志.2007,13(5).
[32]Shurin G V,Aalamian M,Pirtskhalaishvili G,et al.Human prostate cancer blocks the generation of dendritic cells from CD34+ hematopoietic progenitors[J].European urology.2001,39:37-40.
[33]Aalamian M,Pirtskhalaishvili G,Nunez A,et al.Human prostate cancer regulates generation and maturation of monocyte-derived dendritic cells[J].The Prostate.2001,46(1).
[34]Pirtskhalaishvili G,Shurin G V,Esche C,et al.Cytokine-mediated protection of human dendritic cells from prostate cancer-induced apoptosis is regulated by the Bcl-2 family of proteins[J].British Journal of Cancer.2000,83:506-513.
[35]Gabrilovich D I.Decreased antigen presentation by dendritic cells in patients with breast cancer[J].Clinical Cancer Research.1997,3(3):483-490.
[36]Bonifaz L,Bonnyay D,Mahnke K.Efficient targeting of protein antigen to the dendritic cell receptor DEC 2 205 in the steady state leads to antigen presentation on major histocompatibility complex class Iprod 2 ucts and peripheral CD8+ T cell tolerance[J].J Exp Med.2002,196(12):627-1638.
[37]Shurin M R,Lu L,Ka]inski P,et al.Th1/Th2 balance in cancer,transplantation and pregnancy[C].Springer,1999.
[38]Ho C S,Lopez J A,Vuckovic S,et al.Surgical and physical stress increases circulating blood dendritic cell counts independently of monocyte counts[J]. Blood.2001,98(1):140.
[39]Burch P A,Breen J K,Buckner J C,et al.Priming Tissue-specific Cellular immunity in a Phase I Trial of Autologous Dendritic Cells for Prostate Cancer 1[Z].AACR,2000:6,2175-2182.
[40]Alessandro S,Miriam L,Annamaria A O,et al.Characterization of circulating blood dendritic cell subsets DC123+(Lymphoid) and DC11C+(myeloid)in prostate adenocarcinoma patients[J].The Prostate.2007,67(1).
[41]Harzstark A L,Small E J.Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells:APC8015(ProvengeR)[J].Expert Opinion on Biological Therapy.2007,7(8):1275-1280.
[42]李绍杰.激素难治性前列腺癌治疗进展[J].老年医学与保健.2007,13(006):389-392.
[43]Triozzi P L,Khurram R,Aldrich W A,et al.Intratumoral injection of dendritic cells derived in vitro in patients with metastatic cancer[J].Cancer.2000.89(12).
[44]张晓光,徐勇.前列腺癌免疫治疗的进展[J].国外医学:泌尿系统分册.2004,24(002):172-177.
[45]Tarassoff C P,Arlen P M,Gulley J L.Therapeutic vaccines for prostate cancer[J].The Oncologist.2006,11(5):451-462.
[46]Fong L,Brockstedt D,Benike C,et al.Dendritic Cell-Based Xenoantigen Vaccination for Prostate Cancer Immunotherapy 1[J].The Journal of Immunology.2001,167(12):7150-7156.
[47]Small E J,Fratesi P,Reese D M,et al.Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells[J].Journal of Clinical Oncology.2000,18(23):3894.
[48]Murphy G,Tjoa B,Ragde H,et al.Phase I clinical trial:T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen[J].The Prostate.1996,29(6).
[49]Tjoa B A,Lodge P A,Salgaller M L,et al.Dendritic cell-based immunotherapy for prostate cancer[J].CA:A Cancer Journal for Clinicians.1999,49(2):117-128.
[50]Heiser A,Coleman D,Dannull J,et al.Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors[J].Journal of Clinical Investigation. 2002,109(3):409-417.
[51]Vonderheide R H,Domchek S M,Schultze J L,et al.Vaccination of cancer patients against telomerase induces functional antitumor CDS+ T lymphocytes[Z].AACR,2004:10,828-839.
[52]Mu L J,Kyte J A,Rvalheim G,eL al.Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients[J].British journal of cancer.2005,93:749-756.
[53]Su Z,Dannull J,Yang B K,et at.Telomerase mRNA-Transfected Dendritic Cells Stimulate Antigen-Specific CD8+ and CD4+ T Cell Responses in Patients with Metastatic Prostate Cancer 1[J].The Journal of Immunology.2005,174(6):3798-3807.
[54]Ribas A.Genetically modified dendritic cells for cancer immunotherapy[J].Current gene therapy.2005,5:619-628.
[55]覃汉军,张叔人.前列腺癌的免疫基因治疗研究进展[J].中国免疫学杂志.2005.8.
[56]Craft N,Chhor C,Tran C,et al.Evidence for Clonal Outgrowth of Androgen-independent Prostate Cancer Cells from Androgen-dependent Tumors through a Two-Step Process 1[Z].AACR,1999:59,5030-5036.
[57]陈朝晖,肖传国.雄激素受体异常激活与激素非依赖性前列腺癌的形成机制[J].医学分子生物学杂志.2004,1(005):309-312.
[58]Weidner N,Carroll P R,Flax J,et al.Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma.[J].The American Journal of Pathology.1993,143(2):401.
[59]刘秋英,王一飞.血管生成及其抑制剂在前列腺癌中的研究进展[J].中国病理生理杂志.2004,20(012):2347-2352.
[60]Carlson R W,Anderson B O,Burstein H J.NCCN Clinical Practice Guidelines in Oncology[J].Breast Cancer.2006.
[61]那彦群.中国泌尿外科疾病诊断治疗指南[Z].北京:人民卫生出版社,2006.
[62]Han K R,Seligson D B,LiuX,et al.Prostate stem cell antigen expression is associated with gleason score,seminal vesicle invasion and capsular invasion in prostate cancer[J].The Journal of Urology.2004,171(3):1117-1121.
[63]Ross S,Spencer S D,Holcomb I,et al.Prostate Stem Cell Antigen as Therapy Target Tissue Expression and in Vivo Efficacy of an Immunoconjugate[Z].AACR,2002:62,2546-2553.
[64]许传亮,顾正勤,孙颖浩,等.抗人前列腺干细胞抗原单克隆抗体的前列腺癌免疫病理研究[J].上海医学.2005,28(005):363-365.
[65]姜涛,姜辉,宋希双,等.前列腺癌中P53的表达及其临床意义[J].中华男科学杂志.2005,11(006):448-451.
[66]Singh H,Canto E I,Shariat S F,et al.Improved detection of clinically significant,curable prostate cancer with systematic 12-core biopsy[J].The Journal of Urology.2004,171(3):1089-1092.
[67]史密斯.泌尿外科学[Z].北京:人民卫生出版社,2005.
[68]肖芹,印洪林,陆珍凤,等.前列腺癌G1eason分级评分与血清PSA,原位PSA的变化和34βE12,P504S免疫表型的研究[J].中华男科学杂志.2004,10(005):362-365.
[69]Carroll P R.Normograms are superior to staging and risk grouping systems for identifying high-risk patients:preoperative application in prostate cancer[J].Urol ONcol.2003,21(6):484-485.
[70]Oh W K.The evolving role of estrogen therapy in prostate cancer[J].Clinical Genitourinary Cancer.2002,1(2):81-89.
[71]李汉忠,严维刚.前列腺癌近距离治疗的研究进展[J].中华外科杂志.2005,43(002):129-131.
[72]叶敏.前列腺癌的间歇雄激素了阻断疗法(附编者按)[J].中华泌尿外科杂志.2001,22(002):116-118.
[73]徐勇刚,李高峰.前列腺癌的放射治疗进展[J].中华老年医学杂志.2006,25(001):68-70.
[74]Saad F,Guise T,Hussain A,et al.The role of intravenous bisphosphonates in the management of prostate cancer:treatment guidelines[J].Am J Urol Rev.2004,2(suppl 2):9-15.
[75]楚延春,张同斌.前列腺癌的病因病机浅探[J].河南中医药学刊.1997,12(004):14-16.
[76]彭煜,彭培初.泉安方治疗晚期前列腺癌骨转移痛初探(附18例报告)[J].中国男科学杂志.2004,18(004):46-48.
[77]李恒山,杨玉霞.中医药治疗晚期前列腺癌12例报告[J].四川中医.2004,22(005):48-48.
[78]吕立国,古炽明,王昭辉,等.陈志强教授对晚期前列腺癌中医病因病机的探讨[J].新中医.2007,39(002):81-82.
[79]张剑.李辅仁治疗前列腺癌睾丸摘除术后诸症的经验[J].中医杂志.1998,39(002):83-83.
[80]厉将斌,王沛.前列腺癌中医药治疗的经验与思路[J].中国中西医结合杂志.2002,22(006):425-425.
[81]丁永锋,张亚大,朱子军,等.77例前列腺癌中医证型特点与临床相关因素分析[J].中国中西医结合外科杂志.2006,12(006):528-530.
[82]朱晓光.晚期前列腺癌的中医药治疗现状[J].现代中西医结合杂志.2006,15(011):1552-1553.
[83]吕立国,代睿欣,王昭辉,等.陈志强教授扶正抑瘤法治疗晚期前列腺癌临床经验介绍[J].新中医.2007,39(005):91-92.
[84]陈佑邦.中华人民共和国中医药行业标准——中医病证诊断疗效标准[Z].南京:南京大学出版社,1994.
[85]Wang R G,You Z L,Feng G R.Study on the plant estrogen in Chinese herbal medicine[J].Zhongguo Zhong Xi Yi Jie He Za Zhi.2004,24(2):169-171.
[86]宋丽华.植物性雌激素的研究进展[J].国外医学:药学分册.2003,30(001):25-29.
[87]Rosenberg Z R,Jenkins D J,Brown T J,et al.Flavonoids can block PSA production by breast and prostate cancer cell lines[J].Clinica chimicaacta.2002,317(1-2):17-26.
[88]魏道智,郭澄,刘皋林.抗癌中药中微量元素与抗癌活性的相关性[J].中国医学生物技术应用杂志.2003,12(8):12-19.
[89]钱韵旭,赵浩如,高展.白花蛇舌草提取物的体外抗肿瘤活性[J].江苏药学与临床研究.2004,12(004):36-38.
[90]王宇翎,张艳,方明,等.白花蛇舌草总黄酮的免疫调节作用[J].中国药理学通报.2005,21(004):444-447.
[91]于春艳,李薇,刘玉和,等.白花蛇舌草提取物体外抗肿瘤作用及机制研究[J].北华大学学报:自然科学版.2004,5(005):412-416.
[92]谭永红.中药半枝莲的研究进展[J].西南国防医药.2002(02).
[93]庞雅琴,罗琼,李卓能,等1.番茄汁对人前列腺癌细胞DNA损伤作用的影响[J].中国公共卫生.2005,21(001):37-38.
[94]Agarwal R,Wang Z Y,Mukhtar H.Inhibition of mouse skin tumor-initiating activity of DMBA by chronic oral feeding of glycyrrhizin in drinking water[J].Nutr Cancer.1991,15(3-4):187-193.
[95]Lee S C,Kuan C Y,Yang C C,et al.Bioflavonoids commonly and potently induce tyrosine dephosphorylation/inactivation of oncogenic proline-directed protein kinase FA in human prostate carcinoma cells.[J].Anticancer research.1998,18(2A):1117.
[96]张红.女贞子的药理作用研究状况[J].时珍困药研究.1997,8(003):275-276.
[97]黄镜,孙燕.熊果酸的抗肿瘤活性[J].中国新药杂志.1997,6(002):101-104.
[98]陈朝晖,赵军,肖亚军,等.姜黄素诱导人前列腺癌细胞株PC-3凋亡的研究[J].中华实验外科杂志.2005,22(004):507-507.
[99]魏道智,郭澄.中药蝼蛄中微量元素与临床药效的相关性分析[J].广东微量元素科学.2002,9(010):64-67.
[100]顾正勤,孙颖浩,许传亮,等.黄芩苷诱导前列腺癌细胞株DU145凋亡的体外研究[J].中国中药杂志.2005,30(001):63-66.
[101]谌科,胡志全,叶章群.姜黄素和顺铂联用对雄激素非依赖性前列腺癌细胞PC-3作用[J].中国医院药学杂志.2005,25(006):542-544.
[102]刘雪莉,孙静芸.枸杞子抑制人前列腺细胞增殖活性成分的提取与分离[J].中国中药杂志.2000,25(008):481-483.
[103]Darzynkiewicz Z,Traganos F,Wu J M,et al.Chinese herbal mixture PC SPES in treatment of prostate cancer(review)[J].International Journal of Oncology.2000,17(4):729-736.
[104]张群豪,陈可冀.美国PC—SPES(中药复方)抗前列腺癌进展续报[J].中国中西医结合杂志.2002,22(4):297-297.
[105]师长进,俞莉章,那彦群,等.中药紫龙金对转移性前列腺癌体外增殖及侵袭能力的影响[J].中华外科杂志.2003,41(006):473-473.
[106]杜广,郭鹏,郭剑明,等.德士康对前列腺癌激素非依赖型细胞株细胞周期的抑制作用[J].肿瘤.2005,25(002):136-139.
[107]Giordano F J,Johnson R S.Angiogenesis:the role of the microenvironment in flipping the switch[J].Current Opinion in Genetics & Development.2001,11(1):35-40.
[108]Dotal T,Cao Y C,Dorai B,et al.Therapeutic Potentialof Curcuminin Human Prostate Cancer.Ⅲ.Curcumin Inhibits Proliferation,Induces Apoptosis,and Inhibits Angiogenesisof LNCaPProstate Cancer Cells InVivo[J].The Prostate.2001,47:293-303.
[109]王毅,郝钰,邱全瑛,等.人参皂苷Rg1,Rh1对树突状细胞刺激T细胞增殖及LPAK抗肿瘤活性的影响[J].中国免疫学杂志.2003,19(004):248-252.
[110]Vermeiren J,Ceuppens J L,Van G M,et al.Human T Cell Activation by Costimulatory Signal-Deficient Allogeneic Cells Induces Inducible Costimulator-Expressing Anergic T Cells with Regulatory Cell Activity 1[J]. The Journal of Immunology.2004,172(9):5371-5378.
[111]张印,郭建刚.中药保元丹对肺癌患者化疗后T淋巴细胞功能的影响[J].第四军医大学学报.2005,25(13).
[112]李道明.中药对辅助化疗患者免疫功能的影响[J].湖北中医杂志.2005,27(009):44-44.
[113]陈学林,袁杰,刘承云,等.参芪扶正注射液配合化疗改善老年消化道肿瘤48例机体状况的观察[J].陕西中医.2006,27(003):287-288.
[114]吴皓,林洪生,裴迎霞,等.人参皂甙Rg3对荷瘤及环磷酰胺化疗小鼠黏膜免疫力影响[J].中国肿瘤.2006,15(006):369-371.
[115]Kushibiki T,Matsumoto K,Nakamura T,et al.Suppression of tumor metastasis by NK4 plasmid DNA released from cationized gelatin[J].Gene therapy.2004,11(15):1205-1214.
[116]周昌艳,唐庆九,杨焱,等.灵芝中有效成分灵芝酸的抑制肿瘤作用研究[J].菌物学报.2004,23(002):275-279.
[117]宁安红,曹婧,黄敏,等.灵芝多糖对荷瘤小鼠肿瘤免疫系统的影响[J].中国微生态学杂志.2004,16(001):13-14.
[118]李泽庚,张杰根,彭波,等.肺气虚证和肺阴虚证患者外周血NK细胞表达分析[J].中医杂志.2005,46(007):533-534.
[119]赵丽红,徐蔚杰.正得康对非小细胞肺癌患者扶正作用的临床观察[J].实用中西医结合临床.2004,4(004):23-23.
[120]刘海涛,戴锡孟.中药扶正合剂对LA795转移性肺癌小鼠的抑瘤作用和机制研究[J].江苏中医药.2004,25(010):56-58.
[121]冯磊,寿春晖,冯永生,等.中药扶正配方在消化道肿瘤治疗中的作用[J].浙江中西医结合杂志.2006,16(005):272-274.
[122]朱小东,王安宇,王绍丰,等.中药扶正抗癌胶囊2号对荷瘤小鼠的免疫效应[J].中国肿瘤临床与康复.2003,10(006):517-518.
[123]李杰,宋淑霞,韩丽枝,等.益气补肾方药对化疗荷瘤小鼠免疫功能的影响[J].中国实验动物学报.2004,12(003):152-155.
[124]汪永锋,张延英,李广远,等.贞芪酪蛋白复合肽对大鼠巨噬细胞功能的调节作用[J].中医研究.2006,19(003):22-24.
[125]毕明星,刘作金,王华丽,等.肝癌-1号对大鼠巨噬细胞杀伤肝癌细胞能力的影响及机制[J].世界华人消化杂志.2006,14(005):526-529.
[126]Reome J B,Hylind J C,Dutton R W,et al.Type 1 and type 2 tumor infiltrating effector cell subpopulations in progressive breast cancer[J].Clinical Immunology.2004,111(1):69-81.
[127]Hsiao Y W,Liao K W,Hung S W,et al.Tumor-Infiltrating Lymphocyte Secretion of IL-6 Antagonizes Tumor-Derived TGF-β1 and Restores the Lymphokine-Activated Killing Activity 1[J].The Journal of Immunology.2004,172(3):1508-1514.
[128]黄立中,伍参荣,王云启,等.益气平悬饮提取物对肺癌胸水中肿瘤浸润淋巴细胞杀伤活性的影响[J].中医药学刊.2004,22(002):230-232.
[129]吴良村,陈良良,李庆霞,等.康莱特对肿瘤浸润淋巴细胞的体外扩增及抗肿瘤作用的研究[J].中国医药学报.2004,19(011):656-658.
[130]张宏方,马振亚,胥冰,等.中药调衡方对S180与H22荷瘤小鼠TNF与LAK细胞活性的影响[J].陕西中医.2005,26(009):983-985.
[131]席亚明,王镜.梁金菇多糖对荷瘤鼠的抗肿瘤作用和免疫功能影响[J].华西医学.2005,20(001):43-44.
[132]刘丽宏,单保恩,刁兰萍,等.参芪扶正注射液对血液系统恶性肿瘤患者红细胞免疫功能的影响[J].浙江中医杂志.2003,38(012):542-542.
[133]李雪峰,赵健雄.扶正抑瘤颗粒对食管癌放疗患者红细胞免疫功能的影响[J].上海中医药杂志.2004,38(007):51-52.
[134]陈德轩,潘立群.术后应用爱迪注射液对食管癌红细胞免疫影响的临床研究[J].东南大学学报:医学版.2004,23(002):117-119.
[135]任为,王又红.芪瑞扶正胶囊对免疫抑制小鼠红细胞免疫的影响[J].山东中医杂志.2004,23(001):36-38.
[136]查占山,钱宝华,郭峰,等.红细胞CD35在抗原激活淋巴细胞免疫反应中的作用[J].解放军医学杂志.2006,31(002):104-105.
[137]王运田,单保思,李巧霞.黄芪提取物免疫调节活性的体外研究[J][J].中国中西医结合杂志.2002,22(6):453-455.
[138]付于,夏天.消瘤汤治疗肿瘤及调节免疫功能的实验研究[J].中国中西医结合杂志.2004,24(012):1114-1117.
[139]李益民,张瑛.参希胶囊对肿瘤患者细胞免疫功能的影响[J].国医论坛.2004,19(002):21-22.
[140]薛兴奎,张玲,王芸,等.ICA,PJA逆转人高转移肺癌细胞Fas/FasL途径免疫逃逸机制的研究[J].中国免疫学杂志.2004,20(002):102-105.
[141]赵健雄,朱玉真,沈世林,等.扶正抑瘤颗粒对荷瘤(H22)小鼠T淋巴细胞Fas/FasL蛋白表达的影响[J].中国中医药科技.2006,13(001):14-15.
[142]崔澂,王润田.TGF-β介导的肿瘤免疫抑制研究及临床意义[J].实用肿瘤杂志.2005,5.
[143]何彦丽,应逸,罗荣敬,等.枸杞多糖对荷瘤小鼠免疫抑制因子VEGF,TGF- β1水平的影响[J].中药新药与临床药理.2005,16(003):172-174.
[144]王薇,李萍萍.中药影响树突状细胞抗肿瘤免疫作用的研究进展[J].临床肿瘤学杂志.2007,8.
[145]邵鹏,赵鲁杭.黄芪多糖对树突状细胞表型及功能成熟的影响[J].中华微生物学和免疫学杂志.2006,26(007):637-640.
[146]邓曼,窦晓兵,史亦谦,等.黄芪多糖体外诱导脐血单核细胞分化为树突状细胞及其免疫学特征[J].医学研究杂志.2006,35(009):22-26.
[147]董静,顾华丽,马承泰,等.大剂量黄芪对急性白血病患儿外周血树突状细胞的诱导和抗原呈递功能的影响[J].中国中西医结合杂志.2005,25(010):872-875.
[148]董竞成,董晓辉.黄芪注射液与白细胞介素2增强树突细胞抗肿瘤转移作用的比较研究[J].中国中西医结合杂志.2005,25(003):236-239.
[149]林志彬.灵芝抗肿瘤活性和免疫调节作用的研究进展[J].北京大学学报:医学版.2002,34(005):493-498.
[150]孙丽华,赵明耀,黄幼田,等.灵芝孢子粉对荷瘤小鼠树突状细胞的影响及其抗瘤效应[J].山西医药杂志.2006,35(008):698-700.
[151]王毅,郝钰,邱全瑛,等.人参皂苷Rg1,Rh1对树突状细胞刺激T细胞增殖及LPAK抗肿瘤活性的影响[J].中国免疫学杂志.2003,19(004):248-252.
[152]方美云,王忠裕,王一.细胞因子联合人参皂甙及三氧化二砷诱导HL-60细胞向树突状细胞分化的实验研究[J].实用癌症杂志.2005,20(001):15-19.
[153]朱杰,赵鲁杭,陈智.枸杞多糖对小鼠骨髓树突状细胞成熟的影响[J].浙江大学学报:医学版.2006,35(006):648-652.
[154]荣微,井欢,刘春英.香菇多糖对荷瘤小鼠树突状细胞功能影响的实验研究[J].中医药学刊.2006,24(004):681-682.
[155]侯安继,杨占秋,黄菁,等.羧甲基茯苓多糖上调HBV转基因小鼠树突状细胞功能[J].武汉大学学报:理学版.2006,52(006):778-782.
[156]郭文菁,杨美香,曲迅,等.罗勒多糖对树突状细胞表面分子表达的影响[J].中国免疫学杂志.2006,22(009):827-829.
[157]杜桂清,孙光,郭连英,等.榄香烯复合瘤苗冲激的树突状细胞的功能研究[J].中国肿瘤生物治疗杂志.2005,12(004):295-297.
[158]陈智超,王红祥,游泳,等.参芪扶正注射液对急性髓系白血病患者树突状细胞作用的体外研究[J].临床内科杂志.2007,24(007):455-457.
[159]杨莉,李艳佳,刘京生,等.复方中药对外周血树突状细胞的干预作用[J].细胞与分子免疫学杂志.2007,23(007):606-608.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |